New Zealand reduces fees, changes abbreviated review rules
This article was originally published in SRA
Executive Summary
New Zealand’s regulatory agency Medsafe has reduced the fees payable for applications for approval of innovative new medicines and for clinical trial approvals1. While the new fees applied from 8 April, the regulatory authority is holding a consultation, and any feedback received by a 22 May deadline will be considered and may result in adjustments.